Zymeworks Inc. (ZYME) insider trading

By person

12 insiders · 69 transactions

8.9×

Kenneth Galbraith holds 8.9 times base salary in stock. $5.86M of shares against $656.76K in salary for 2025.

Salary from the company's own proxy. The shares are what Kenneth Galbraith last reported holding, valued at $25.85, the price Common Stock was last bought or sold at on the open market here, on 9 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

EcoR1 Capital, LLC entity

Director

$89.85M (42)

—

+$89.85M

22,970,388

32.37%

$593.78M

+160.3%

Kenneth Galbraith

Chair & CEO

—

$4.45M (8) scheduled

−$4.45M

226,842

0.3197%

$5.86M

—

Paul Andrew Moore

Chief Scientific Officer

—

$1.14M (7) scheduled

−$1.14M

48,497

0.0683%

$1.25M

—

Jeffrey T L Smith

EVP & Chief Medical Officer

—

$641.37K (3) scheduled

−$641.37K

26,708

0.0376%

$690.40K

—

Adam Schayowitz

EVP, Head of R&D

—

$357.56K (1) scheduled

−$357.56K

23,205

0.0327%

$599.85K

—

Mark Hollywood

EVP & Chief Operating Officer

—

$138.76K (1) scheduled

−$138.76K

133,852

0.1886%

$3.46M

+10.3%

Christopher Astle

SVP & Chief Financial Officer

—

$78.08K (4) scheduled

−$78.08K

6,503

0.0092%

$168.10K

+870.6%

Neil A Klompas

President & COO

—

$23.30K (1) scheduled

−$23.30K

17,032

0.0240%

$440.28K

+15.1%

Neil Josephson

Chief Medical Officer

—

$20.05K (1) scheduled

−$20.05K

14,449

0.0204%

$373.51K

+30.9%

Redmile Group, LLC entity

10% owner

—

6,075,918

8.56%

$157.06M

+0.5%

Gregory Austin Ciongoli

Director

—

488,500

0.6884%

$12.63M

+564.6%

Leone D Patterson

EVP, Chief Bus & Fin Officer

—

459

0.0006%

$11.87K

—

Zymeworks Inc.

What the insiders did Net buying

By person